Related Experiment Video
Updated: Mar 9, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins
Isa N Cruz1, Helen M Coley2, Holger B Kramer3
1Department of Pharmaceutical & Biological Chemistry, UCL School of Pharmacy, London, U.K.
Background:
Carboplatin and paclitaxel form the cornerstone of chemotherapy for epithelial ovarian cancer, however, drug resistance to these agents continues to present challenges. Despite extensive research, the mechanisms underlying this resistance remain unclear.
Materials And Methods:
A 2D-gel proteomics method was used to analyze protein expression levels of three human ovarian cancer cell lines and five biopsy samples. Representative proteins identified were validated via western immunoblotting. Ingenuity pathway analysis revealed metabolomic pathway changes.
Results:
A total of 189 proteins were identified with restricted criteria. Combined treatment targeting the proteasome-ubiquitin pathway resulted in re-sensitisation of drug-resistant cells. In addition, examination of five surgical biopsies of ovarian tissues revealed α-enolase (ENOA), elongation factor Tu, mitochondrial (EFTU), glyceraldehyde-3-phosphate dehydrogenase (G3P), stress-70 protein, mitochondrial (GRP75), apolipoprotein A-1 (APOA1), peroxiredoxin (PRDX2) and annexin A (ANXA) as candidate biomarkers of drug-resistant disease.
Conclusion:
Proteomics combined with pathway analysis provided information for an effective combined treatment approach overcoming drug resistance. Analysis of cell lines and tissues revealed potential prognostic biomarkers for ovarian cancer.
Insights
Drug resistance in ovarian cancer is a challenge. Proteomics identified new biomarkers and a combined treatment targeting the proteasome-ubiquitin pathway to overcome resistance in epithelial ovarian cancer.
Area of Science:
- Oncology
- Proteomics
- Biochemistry
Background:
- Carboplatin and paclitaxel are standard treatments for epithelial ovarian cancer.
- Drug resistance to these chemotherapies remains a significant clinical challenge.
- Mechanisms underlying ovarian cancer drug resistance are not fully understood.
Purpose of the Study:
- To investigate protein expression changes in drug-resistant ovarian cancer.
- To identify potential biomarkers for drug-resistant ovarian cancer.
- To explore therapeutic strategies to overcome drug resistance.
Main Methods:
- Proteomic analysis using 2D-gel electrophoresis on ovarian cancer cell lines and patient biopsies.
- Validation of protein candidates via western immunoblotting.
- Ingenuity pathway analysis to identify affected biological pathways.
Main Results:
- 189 proteins were identified, with several candidate biomarkers for drug resistance including alpha-enolase (ENOA).
- Combined treatment targeting the proteasome-ubiquitin pathway re-sensitized resistant cells.
- Identified potential prognostic biomarkers in ovarian cancer tissues.
Conclusions:
- Proteomics and pathway analysis can guide effective combination therapies against drug resistance.
- Identified proteins like ENOA may serve as prognostic biomarkers for ovarian cancer patients.
